Oceania · General news · The Courier-Mail
Lunch Wrap: Nvidia’s drama gets a new episode as Xero grabs the popcorn
Detailed summary
Clarity Pharmaceuticals (ASX:CU6) has scored the FDA’s first Breakthrough Therapy designation for a PSMA PET imaging agent, with its copper-64 SAR-bisPSMA scan showing promise in…
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.couriermail.com.au)
